Glenmark raises sustainability-linked loan of USD 228 million
Glenmark will use the fund to refinance a USD 182.5 million syndicated loan, closed in November 2020, Mani added.
New Delhi: In the industry's first, pharma major Glenmark has raised USD 228 million in sustainability-linked loan (SLL) from a consortium of foreign lenders, led by Bank of America.
Bank of America, the sole underwriter of the entire loan, has extended USD 50 million, and Cincinnati, Ohio-based Fifth Third Bank chipped in with 30 million, the company said.
"We have raised an SLL of USD 228 million under the ECB (external commercial borrowing) category at a significantly lower cost to refinance its existing ECB debt. This we believe is the first SLL loan by a domestic pharmaceutical company," Glenmark Executive Director and Chief Financial Officer VS Mani told PTI on Tuesday.
The five-year loan is priced at 175 basis points (bps) over the London interbank offered rate, or Libor which is being replaced by the SOFR, or the secured overnight financing rate.
The SOFR is the benchmark interest rate for dollar-denominated derivatives and loans that is replacing the scam-ridden Libor.
The interest margin will come down by 2.5 bps if the borrower meets both the sustainability metrics relating to emissions reduction and water consumption, the Bank of America explained.
Glenmark will use the fund to refinance a USD 182.5 million syndicated loan, closed in November 2020, Mani added.
The other lenders in the consortium include the leading Taiwanese lender CTBC Bank, Emirates NBD and Qatar National Bank Singapore branch, which gave USD 24 million each. While Mashreq Bank and Japan's MUFG and Siemens Bank Singapore branch extended USD 20 million.
ING Bank and KEB Hana Bank Bahrain branch chipped in with USD 8 million each.
Read also: Glenmark gets CDSCO panel nod for Phase 4 study of anti-diabetic FDC drug
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.